Corbevax becomes the third India-made vaccine that may be available for use in children.
Hyderabad-based pharmaceutical company Biological E. Limited has been approved by the Drugs Controller General of India (DCGI) to conduct further trials of its vaccine Corbevax on children and adolescents.
Highlights:
♦ The Drugs Controller General of India approved Biological E to perform two clinical trials of its Covid-19 vaccine candidate Corbevax.
♦ with this, the local drugmaker can start a mid-term study of the Covid-19 vaccine for children and adolescents.
♦ The Hyderabad-based pharmaceutical company has received approval to perform Phase 2 & 3 clinical trials of its anti-Covid injection called Corbevax, which is suitable for children aged 5 to 18 with certain conditions.
♦ After the recommendations from the Subject Expert Committee, the permission has been approved by Biological E.
♦ The central government has paid Biological E an advance payment of 15 billion rupees for the purchase of 30 crore for the Covid-19 vaccine
